title: Hypoglycemic and hypolipidemic effects of neohesperidin derived from Citrus aurantium L. in diabetic KK-A(y) mice.
abstract: The present study is to investigate the possible hypoglycemic and hypolipidemic effects of neohesperidin (NHP) derived from Citrus aurantium L. in vivo. KK-A(y) mice were used as the diabetic experimental model, whereas C57BL/6 mice were used as normal control for a 6-week study. Treatment of NHP significantly decreased fasting glucose, serum glucose, and glycosylated serum protein (GSP) in KK-A(y) mice. It significantly elevated oral glucose tolerance and insulin sensitivity and decreased insulin resistance in the diabetic mice. In addition, NHP significantly decreased serum triglycerides (TG), total cholesterol (TCH), leptin level, and liver index in the KK-A(y) mice. NHP also inhibited lipid accumulation in the liver and decreased the size of epididymal adipocyte in the KK-A(y) mice. Gene expression of stearoyl-CoA desaturase 1 (SCD-1) and fatty acid synthase (FAS) were significantly inhibited, whereas the expression of acyl-CoA oxidase (ACOX) was significantly induced by NHP treatment in the liver of KK-A(y) mice. In addition, elevated level of phosphorylation of hepatic AMPK was observed in NHP-treated mice. Therefore, the activation of the AMPK pathway and regulation of its target genes, including SCD-1, FAS, and ACOX, may play important roles in the hypoglycemic and hypolipidemic effects of NHP in vivo, and NHP may have great potential in the prevention of diabetes and its complications.
authors.affiliation: Laboratory of Fruit Quality Biology, Zhejiang University, Zijingang Campus, Hangzhou, 310058, China. xianli@zju.edu.cn.
authors.forename: Sheng
authors.initials: S
authors.lastname: Jia
authors.forename: Ying
authors.initials: Y
authors.lastname: Hu
authors.forename: Wenna
authors.initials: W
authors.lastname: Zhang
authors.forename: Xiaoyong
authors.initials: X
authors.lastname: Zhao
authors.forename: Yanhong
authors.initials: Y
authors.lastname: Chen
authors.forename: Chongde
authors.initials: C
authors.lastname: Sun
authors.forename: Xian
authors.initials: X
authors.lastname: Li
authors.forename: Kunsong
authors.initials: K
authors.lastname: Chen
mesh_terms: D052436:Adipose Tissue, White / Q000473:pathology; D050154:Adiposity; D000818:Animals; D001798:Blood Proteins; D002957:Citrus / Q000737:chemistry*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000178:diet therapy* / Q000378:metabolism / Q000473:pathology; D003927:Diet, Diabetic; D019587:Dietary Supplements; D015971:Gene Expression Regulation, Enzymologic; D006023:Glycoproteins / Q000097:blood; D006569:Hesperidin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006943:Hyperglycemia / Q000517:prevention & control; D006949:Hyperlipidemias / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D050356:Lipid Metabolism; D008099:Liver / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D008297:Male; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D011897:Random Allocation; D013047:Specific Pathogen-Free Organisms; D000093422:Glycated Serum Proteins
chemical_list: D001798:Blood Proteins; D006023:Glycoproteins; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D006569:Hesperidin; C546526:neohesperidin; D000093422:Glycated Serum Proteins